Targeting validation and pharmacokinetics (PK)/pharmacodynamics (PD) are important components of drug/therapeutic development. PET imaging is a particularly useful tool for therapeutic tracking studies in vivo because it can provide tomographic distribution information with excellent temporal and spatial resolution.
Preclinical PET imaging has been proven in studies of therapeutic targeting and biodistribution, drug target interactions, pharmacodynamics and toxicology. These methods have helped facilitate the development of therapeutic agents that are now clinically available.
Two of the most common uses of preclinical PET imaging in drug discovery are studies of compound targeting and biodistribution and therapeutic efficacy. This application note provides a brief introduction to preclinical PET imaging for such studies.
